Combination chemotherapy of irinotecan combined with bolus 5-fluorouracil, continuous infusion 5-fluorouracil, and high dose leucovorin every two weeks in recurrent or metastatic colorectal cancer / 대한내과학회지
Korean Journal of Medicine
; : 452-458, 2003.
Artigo
em Coreano
| WPRIM (Pacífico Ocidental)
| ID: wpr-79463
Biblioteca responsável:
WPRO
ABSTRACT
BACKGROUND:
Irinotecan is an active agent in colorectal cancer, producing 30~40% response rates when combined with 5-fluorouracil and leucovorin in metastatic colorectal cancer as first line therapy, however, the best combination schedules are not determined yet. We investigated the efficacy and toxicity of irinotecan combined with bolus 5-fluorouracil, continuous infusion 5-fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen) in recurrent or metastatic colorectal cancer in Korean patients.METHODS:
Twenty-two patients with measurable diseases previously untreated with chemotherapy other than adjuvant chemotherapy for advanced colorectal cancer were enrolled onto this study and received the study drugs between June 2000 and December 2001. Treatment consisted of irinotecan (180 mg/m2 over two hours on day 1) followed by leucovorin (200 mg/m2 over two hours), bolus 5-fluorouracil 400 mg/m2 and continuous infusion of 5-fluorouracil (600 mg/m2 over next 22 hours) on day 1 and 2. Chemotherapy was repeated every two weeks until progressive disease.RESULTS:
Of the 20 patients evaluable for response, 8 partial responses were observed with a response rate of 40%. Six additional patients achieved stable disease as their best response, and six progressed. The median time to progression was 5.0 months and median overall survival was 17.3 months. The most frequently observed grade 3~4 toxicities were neutropenia (18%) and diarrhea (4.8%). Two mortalities occurred, though not clearly related to treatment, before the end of chemotherapy.CONCLUSION:
Irinotecan combined with LV5FU2 regimen was effective in advanced colorectal cancer with manageable side effects. Caution should be paid to elderly and poor performance patients to prevent treatment related mortality and morbidity.
Texto completo:
Disponível
Contexto em Saúde:
ODS3 - Saúde e Bem-Estar
/
Doenças Negligenciadas
/
ODS3 - Meta 3.3 Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis
/
ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis
Problema de saúde:
Meta 3.3: Acabar com as doenças tropicais negligenciadas e combater as doenças transmissíveis
/
Diarreia
/
Doenças Negligenciadas
/
Infecções Diarreicas
/
Neoplasias Colorretais
/
Outras Doenças Sanguíneas
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Agendamento de Consultas
/
Neoplasias Colorretais
/
Leucovorina
/
Mortalidade
/
Quimioterapia Adjuvante
/
Diarreia
/
Tratamento Farmacológico
/
Quimioterapia Combinada
/
Fluoruracila
/
Neutropenia
Tipo de estudo:
Estudo prognóstico
Limite:
Idoso
/
Humanos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Ano de publicação:
2003
Tipo de documento:
Artigo